Rapport Therapeutics, Inc. Common Stock (RAPP) Stock

Rapport Therapeutics, Inc. Common Stock (RAPP) is a Healthcare stock trading at $37.30 (as of 2026-06-18), with a market capitalization of $1.89B and a trailing P/E of -15.2. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Rapport Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for central nervous system disorders. Its pipeline includes investigational candidates such as RAP-219 and RAP-199, along with nicotinic acetylcholine receptor programs for indications including focal epilepsy and other CNS conditions.

Valuation — source: SEC EDGAR (first-party)
Price$37.30
Market Cap$1.89B
P/E Ratio-15.2
EV / EBITDA-14.9
Price / Book4.01
Price / Sales94.46
DCF Value (model)$-30.28
DCF Upside vs Price-181.2%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$13.62M
Net Margin-818.8%
Return on Equity-22.8%
Current Ratio27.08
Revenue Growth (YoY)12.2%
EPS Growth (YoY)-24.3%
FCF Growth (YoY)31.0%
Financial Health — source: SEC EDGAR
Altman Z-Score38.21 (safe)
Valuation vs Sector & Industry
Stock P/E-15.2
Sector P/E (Healthcare)21.0
Industry P/E (Pharmaceutical Products)17.3
vs Sector-172.5%
vs Industry-188.0%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderFMR LLC ($224.32M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOAbraham N. Ceesay
Employees69
CountryUS
IPO Date2024-06-07

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Innoviva, Inc. (INVA)
  • Atai Beckley N.V (ATAI)
  • Precigen, Inc. (PGEN)
  • Oruka Therapeutics, Inc. (ORKA)
  • Relay Therapeutics, Inc. (RLAY)
  • Collegium Pharmaceutical, Inc. (COLL)
  • Ardelyx, Inc. (ARDX)
  • MBX Biosciences, Inc. Common Stock (MBX)
RAPP earnings history · RAPP institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.